VolitionRx's (VNRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note released on Thursday,Benzinga reports. They currently have a $5.00 price target on the stock.

Other research analysts have also recently issued reports about the stock. HC Wainwright initiated coverage on shares of VolitionRx in a research report on Tuesday, April 8th. They issued a "buy" rating and a $2.50 price objective on the stock. Wall Street Zen initiated coverage on shares of VolitionRx in a research report on Thursday, May 15th. They issued a "sell" rating on the stock. Finally, Jones Trading upgraded shares of VolitionRx to a "strong-buy" rating and set a $3.00 price objective on the stock in a research report on Tuesday, June 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, VolitionRx presently has a consensus rating of "Moderate Buy" and a consensus target price of $3.50.

VolitionRx Stock Performance

NYSE VNRX traded down $0.00 during trading on Thursday, hitting $0.68. 158,216 shares of the company's stock traded hands, compared to its average volume of 208,210. The stock has a market capitalization of $70.19 million, a price-to-earnings ratio of -1.87 and a beta of 1.20. VolitionRx has a 12-month low of $0.40 and a 12-month high of $0.94. The business has a 50 day moving average of $0.63 and a 200-day moving average of $0.59.

Institutional Investors Weigh In On VolitionRx

Large investors have recently made changes to their positions in the company. Lagoda Investment Management L.P. grew its stake in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. Millennium Management LLC purchased a new position in VolitionRx in the 4th quarter worth approximately $36,000. Silverberg Bernstein Capital Management LLC lifted its holdings in VolitionRx by 42.8% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after purchasing an additional 60,209 shares in the last quarter. Two Sigma Securities LLC purchased a new position in VolitionRx in the 4th quarter worth approximately $29,000. Finally, Northern Trust Corp lifted its holdings in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.